<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664755</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA016511</org_study_id>
    <nct_id>NCT00664755</nct_id>
  </id_info>
  <brief_title>Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity</brief_title>
  <official_title>Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a brief smoking cessation trial in women, comparing transdermal nicotine patch (TNP)
      versus varenicline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This component builds directly upon the results of the previously funded project in
      systematically investigating the impact of short-term ovarian hormone fluctuation on females
      as they try to quit smoking with the aid of either transdermal nicotine patch (TNP) or
      varenicline. Each participant will receive a standardized impulsivity evaluation and a
      laboratory-based cue reactivity assessment before the initiation of smoking cessation.
      Progesterone and estrogen levels will be measured at each of nine visits, thereby providing
      an index of reproductive hormone variation over the course of each participant's quit
      attempt. This novel approach of integrating a human laboratory cue reactivity paradigm
      directly with a treatment outcome study will permit us to assess whether or not smoking cue
      reactivity has predictive utility with respect to cessation outcome. Subjects will be
      randomized to receive one of two active pharmacotherapeutic interventions for smoking
      cessation: TNP vs. varenicline in a randomized, single-blind, double dummy design. While TNP
      has demonstrated modest efficacy in improving smoking cessation outcomes, there is some
      evidence that its efficacy may be more robust in men as compared to women. This project will
      provide important information about a) the impact of ovarian hormone levels on smoking
      cessation outcomes, b) the relationship between smoking cue reactivity and smoking cessation,
      and c) comparison between a new pharmacotherapeutic agent and TNP in women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-of-treatment Abstinence</measure>
    <time_frame>2 weeks</time_frame>
    <description>Carbon monoxide (â‰¤10 parts per million) verified abstinence during the last two weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant randomized to receive active varenicline and placebo transdermal nicotine patch.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal Nicotine Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant randomized to receive active transdermal nicotine patch and placebo varenicline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transdermal nicotine patch</intervention_name>
    <description>Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.</description>
    <arm_group_label>Transdermal Nicotine Patch</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-45. Individuals over the age of 45 will not be included as we are examining the
             effects of menstrual cycle and ovarian hormones.

          -  Daily smokers who smoke at least 10 cigarettes per day for at least past 6 months.

          -  Post menarche and pre menopausal

          -  Regular menstrual cycle between 25 and 35 days

          -  At least three months post delivery and breast feeding

          -  Desire to quit smoking and willingness to participate in a research study.

          -  Women with a history of depression (but not current MDE) and current PMDD will be
             included. Excluding women with these diagnoses would have a major impact on
             feasibility, but because both disorders might impact treatment outcome, individuals
             will be stratified across randomization groups.

        Exclusion Criteria:

          -  Any unstable major axis I psychiatric disorder in the past month

          -  Current substance use disorders other than nicotine and caffeine use, in the past 30
             days.

          -  Any medication that may interfere with psychophysiological monitoring

          -  Unstable medical or serious medical condition in the past 6 months

          -  Hypersensitivity to varenicline or TNP

          -  Use of other tobacco products

          -  Use of other medications with smoking cessation efficacy within 30 days prior to
             enrollment

          -  BMI less than 15 since this could alter hormone levels that affect menstrual phase

          -  Pregnancy

          -  Breast feeding

          -  Status post hysterectomy

          -  Birth control or HRT medication that would effect the menstrual cycle. Currently
             available oral contraceptives contain either a combination of a synthetic estrogen and
             synthetic progestin, or a progestin alone. Estrogen and/or progestin inhibit ovulation
             and alter cervical mucus and the endometrium by suppressing the production of
             follicle-stimulating hormone and the luteinizing hormone surge (Bucci &amp; Carson, 1997)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Saladin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>April 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2018</results_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Kevin Gray, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Menstrual Cycle effects</keyword>
  <keyword>Cue Reactivity</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Impulsivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
varenicline: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.</description>
        </group>
        <group group_id="P2">
          <title>Transdermal Nicotine Patch</title>
          <description>Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
transdermal nicotine patch: Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
varenicline: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.</description>
        </group>
        <group group_id="B2">
          <title>Transdermal Nicotine Patch</title>
          <description>Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
transdermal nicotine patch: Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="7.9"/>
                    <measurement group_id="B2" value="33.0" spread="7.4"/>
                    <measurement group_id="B3" value="31.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End-of-treatment Abstinence</title>
        <description>Carbon monoxide (â‰¤10 parts per million) verified abstinence during the last two weeks of treatment</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
varenicline: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.</description>
          </group>
          <group group_id="O2">
            <title>Transdermal Nicotine Patch</title>
            <description>Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
transdermal nicotine patch: Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>End-of-treatment Abstinence</title>
          <description>Carbon monoxide (â‰¤10 parts per million) verified abstinence during the last two weeks of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>6.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
varenicline: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study.</description>
        </group>
        <group group_id="E2">
          <title>Transdermal Nicotine Patch</title>
          <description>Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
transdermal nicotine patch: Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever, which accompanied rash</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Generalized rash not near patch site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>All</sub_title>
                <counts group_id="E1" events="137" subjects_affected="67" subjects_at_risk="67"/>
                <counts group_id="E2" events="170" subjects_affected="73" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin M. Gray, M.D.</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-6330</phone>
      <email>graykm@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

